HIV DISEASE RESEARCH AGENDA

HIV 疾病研究议程

• 批准号: 5205245
• 负责人: RONALD T. MITSUYASU
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5205245
• 关键词: AIDS; AIDS therapy; HIV infections; antiAIDS agent; biomarker; blood cell count; clinical research; combination chemotherapy; cooperative study; cytokine; data collection; helper T lymphocyte; human immunodeficiency virus 1; human subject; human therapy evaluation; immunotherapy; medical outreach /case finding; passive immunization; prognosis; reverse transcriptase inhibitors; therapy compliance; virus load; zidovudine

This Virology Developmental Research component is designed to utilize and develop virological markers to investigate virus replication at the levels of DNA synthesis (reverse transcription) and gene expression. In addition, these various markers of viral replication would be utilized to investigate viral resistance profiles of individuals infected with human immunodeficiency virus type 1 (HIV-1). The UCLA patient population of the ACTG is ideal for this purpose. 1. To determine if a correlation exists between advanced clinical disease and/or virus expression and expression of viral regulatory genes. 2. To determine the viral resistance profiles of individuals infected with HIV-1 utilizing an in vitro assay on once-passaged isolates or directly on virus from plasma and peripheral blood mononuclear cells (PBMC) (ex vivo). 3. To develop novel assays utilizing PCR to directly monitor the extent of HIV-1 reverse transcription following infection. These assays will be used to monitor the degree of resistance to reverse transcriptase inhibitors of virus from ACTG patients.

该病毒学发展研究部分旨在利用和 开发病毒标记以研究水平的病毒复制 DNA合成（逆转录）和基因表达。 此外， 这些病毒复制的各种标记将用于研究 感染人类的​​个体的病毒抗性特征 免疫缺陷病毒1型（HIV-1）。 UCLA患者人数 ACTG是为此目的的理想选择。 1。确定晚期临床之间是否存在相关性 病毒调节的疾病和/或病毒表达和表达 基因。 2。确定感染个体的病毒抗性特征 使用HIV-1利用曾经通过的分离株上的体外测定或 直接从血浆和外周血单核细胞上进行病毒 （PBMC）（Ex Vivo）。 3。开发利用PCR直接监测范围的新颖测定 感染后HIV-1逆转录。 这些测定 将用于监视电阻的反向程度 ACTG患者病毒的转录酶抑制剂。